Technical Analysis for ADMA - ADMA Biologics Inc

Grade Last Price % Change Price Change
grade B 5.1 -2.30% -0.12
ADMA closed down 2.3 percent on Friday, September 13, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ADMA trend table...

Date Alert Name Type % Chg
Golden Cross Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Walk Strength -2.30%
Wide Bands Range Expansion -2.30%
Overbought Stochastic Strength -2.30%

Older signals for ADMA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Medicine Biotechnology Health Biopharmaceutical Biology Pharmaceutical Industry Immunology Infectious Diseases Antibodies Immune System Antibody Glycoproteins Late Stage Biopharmaceutical
Is ADMA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.72
52 Week Low 2.08
Average Volume 687,370
200-Day Moving Average 3.9985
50-Day Moving Average 4.0238
20-Day Moving Average 4.481
10-Day Moving Average 4.806
Average True Range 0.2805
ADX 35.88
+DI 29.8971
-DI 11.3276
Chandelier Exit (Long, 3 ATRs ) 4.6429
Chandelier Exit (Short, 3 ATRs ) 4.5615
Upper Bollinger Band 5.3802
Lower Bollinger Band 3.5818
Percent B (%b) 0.84
BandWidth 40.133899
MACD Line 0.3532
MACD Signal Line 0.2675
MACD Histogram 0.0857
Fundamentals Value
Market Cap 131.55 Million
Num Shares 25.8 Million
EPS -1.77
Price-to-Earnings (P/E) Ratio -2.88
Price-to-Sales 5.85
Price-to-Book 2.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.49
Resistance 3 (R3) 5.51 5.40 5.43
Resistance 2 (R2) 5.40 5.30 5.39 5.40
Resistance 1 (R1) 5.25 5.24 5.20 5.23 5.38
Pivot Point 5.14 5.14 5.11 5.13 5.14
Support 1 (S1) 4.99 5.04 4.94 4.97 4.82
Support 2 (S2) 4.88 4.98 4.87 4.80
Support 3 (S3) 4.73 4.88 4.78
Support 4 (S4) 4.71